Clinical Significance of Biomarkers in Oncology and its Application in Advanced Biosensing technology- A Comprehensive Review
DOI:
https://doi.org/10.58260/j.ppmr.2202.0105Keywords:
Oncology, Biosensing technology, cancer, human deathAbstract
cancer is the second lethal cause of human death globally and based on published literatures, approximately 9.6 million deaths accounted in 2018.1 There are several major causes of cancers: which includes, tobacco and alcohol consumption, poor hygiene less fibrous diet, lack of physical activity or some chronic infections caused by Helicobacter pylori, Human papilloma virus (HPV), Hepatitis B and C virus and Epstein-Barr virus etc.2-5According to World Health Organization report, (WHO, 12 September 2018) the most common cancers are lung, breast, colorectal, prostate, skin (non-melanoma) and stomach cancer. Aging and poor hygienic condition causes formation of free radical leading to oxidative damage to mature cells. Formation of free radicals are responsible for genomic alteration and attenuates age related oxidative damage repair mechanism in our body by suppressing different cytokines and other immunomodulaents; which is closely related to progression of different kind of cancers.6 Apart from that, different other causative mechanisms; i.e., microbial attack in host cells, viral infection, cell necrosis caused by radiations also contributes mutation in specific cells employed in the pathogenesis of different types of cancers. Among the Different therapeutic modalities of cancer, surgery has been proved to be most effective globally, before metastatic stage.7
References
Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. International Agency for Research on Cancer, World Health Organization, Press Release, Geneva, Switzerland, 12th September, 2018.
Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk. L. E. Wroblewski, R. M. Peek, Jr., and K. T. Wilson; Clin. Microbiol. Rev. 2010, 23(4), 713–739.
Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells. S. Stevanovic, S. R. Helman, J. R. Wunderlich, M. M. Langhan, S. L. Doran, M. L. M. Kwong, R. P. Somerville, C. Austin Klebanoff, U. Kammula, R. M. Sherry, J. C. Yang, S. A. Rosenberg, C. S. Hinrichs; J. Clin. Oncology, 2018, 36(15), 3004-3004.
Hepatitis B and C Viruses and Hepatocellular Carcinoma. B. Bartosch; Viruses, 2010, 2, 1504- 1509.
The role of Epstein-Barr virus in cancer. S. B. Pattle and P. J. Farrell; Expert Opin. Biol. Ther.2006, 6(11), 1193-1205.
The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks. J. R. Aunan, W. C. Cho, and K. Søreide; Aging Dis. 2017, 8(5), 628–642.
B. Brett Finlay, Grant McFadden; Anti-Immunology: Evasion of the Host Immune System by Bacterial and Viral Pathogens;2006, Cell 124, 767–782,
Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. K. J. Napier, M. Scheerer and S. Misra; World J. Gastrointest. Oncol.2014, 6(5), 112–120.
Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. L. Warner, J. Chudasama, C. G. Kelly, S. Loughran, K. McKenzie, R. Wight, P. Dey; Cochrane Database of Systematic Reviews, 2014, Issue 12. Art. No.: CD002027.
Cisplatin and its analogues in the treatment of advanced breast cancer: a review. I. E. Smith and D. C. Talbot; Br. J. Cancer. 1992, 65(6), 787–793.
Expression of p53 in Cisplatin-resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-Diaminocyclohexane)(trans-diacetato)(dichloro)- platinum(IV). G. S. Hagopian, G. B. Mills, A. R. Khokhar, R. C. Bast, Jr., and Z. H. Siddik. Clin. Cancer Res. 1999, 5, 655– 663.
Dye Sensitizers for Photodynamic Therapy. A. B. Ormond and H. S. Freeman; Materials, 2013, 6(3), 817-840.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.